The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Therapeutic antibodies for human diseases at the dawn of the twenty-first century
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“Both trastuzumab and rituximab seem to exert their effects primarily through an Fc-receptor-dependent mechanis”
BackgroundPhage antibodies: filamentous phage displaying antibody variable domains
McCafferty, J., Griffiths, A. D., Winter, G., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,423
Maini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05246-0 · Cited by 2,345
Replacing the complementarity-determining regions in a human antibody with those from a mouse
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.
Morrison, S. L., Johnson, M. J., Herzenberg, L. A., & Oi, V. T. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.21.6851 · Cited by 1,039
Assembly of a Functional Immunoglobulin F v Fragment in Escherichia coli
Skerra, A., & Plückthun, A. (1988) · Science · doi:10.1126/science.3285470 · Cited by 978
"Diabodies": small bivalent and bispecific antibody fragments.
Holliger, P., Prospero, T., & Winter, G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6444 · Cited by 874
Antibodies, viruses and vaccines
Burton, D. R. (2002) · Nature Reviews Immunology · doi:10.1038/nri891 · Cited by 637
Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D., & Weiner, L. M. (2001) · PubMed · Cited by 629
Antibody arrays for high-throughput screening of antibody–antigen interactions
de Wildt, R. M. T., Mundy, C. R., Gorick, B. D., & Tomlinson, I. M. (2000) · Nature Biotechnology · doi:10.1038/79494 · Cited by 624
Stability engineering of antibody single-chain Fv fragments
Wörn, A., & Plückthun, A. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4265 · Cited by 616
Escherichia coli Secretion of an Active Chimeric Antibody Fragment
Better, M., Chang, C. P., Robinson, R. R., & Horwitz, A. H. (1988) · Science · doi:10.1126/science.3285471 · Cited by 579
PEGylated antibodies and antibody fragments for improved therapy: a review
Chapman, A. P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00026-1 · Cited by 556
Production of functional chimaeric mouse/human antibody
Boulianne, G. L., Hozumi, N., & Shulman, M. J. (1984) · Nature · doi:10.1038/312643a0 · Cited by 550
Hybrid hybridomas and their use in immunohistochemistry
Milstein, C., & Cuello, A. C. (1983) · Nature · doi:10.1038/305537a0 · Cited by 517
Multiple Roles for the Major Histocompatibility Complex Class I– Related Receptor FcRn
Ghetie, V., & Ward, E. S. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.739 · Cited by 474
Sandborn, W. J., & Hanauer, S. B. (1999) · Inflammatory Bowel Diseases · doi:10.1097/00054725-199905000-00008 · Cited by 454
Hanes, J., Schaffitzel, C., Knappik, A., & Plückthun, A. (2000) · Nature Biotechnology · doi:10.1038/82407 · Cited by 373
Dhodapkar, K. M., Krasovsky, J., Williamson, B., & Dhodapkar, M. V. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011097 · Cited by 349
Human Immune Respone to Monoclonal Antibodies
Khazaeli, M. B., Conry, R. M., & LoBuglio, A. F. (1994) · Journal of Immunotherapy · doi:10.1097/00002371-199401000-00006 · Cited by 301
Schier, R., Bye, J., Apell, G., McCall, A., Adams, G. P., Malmqvist, M., Weiner, L. M., & Marks, J. D. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0004 · Cited by 292
Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity
Maynard, J. A., Maassen, C. B. M., Leppla, S. H., Brasky, K., Patterson, J. L., Iverson, B. L., & Georgiou, G. (2002) · Nature Biotechnology · doi:10.1038/nbt0602-597 · Cited by 287
Glennie, M. J., McBride, H. M., Worth, A. T., & Stevenson, G. T. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.7.2367 · Cited by 263
The antiviral activity of antibodies in vitro and in vivo
Parren, P. W. H. I., & Burton, D. R. (2001) · Advances in Immunology · doi:10.1016/s0065-2776(01)77018-6 · Cited by 261
Directed Evolution of High-Affinity Antibody Mimics Using mRNA Display
Xu, L., Aha, P., Gu, K., Kuimelis, R. G., Kurz, M., Lam, T., Lim, A. C., Liu, H., Lohse, P. A., Sun, L., et al. (2002) · Chemistry & Biology · doi:10.1016/s1074-5521(02)00187-4 · Cited by 251
Jespers, L. S., Roberts, A., Mahler, S. M., Winter, G., & Hoogenboom, H. R. (1994) · Nature Biotechnology · doi:10.1038/nbt0994-899 · Cited by 233
Green, L. L. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(99)00137-4 · Cited by 229
Larson, R., Boogaerts, M., Estey, E., Karanes, C., Stadtmauer, E., Sievers, E., Mineur, P., Bennett, J., Berger, M., Eten, C., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402677 · Cited by 221
Choy, E. H. S. (2002) · Rheumatology · doi:10.1093/rheumatology/41.10.1133 · Cited by 213
Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics
Kipriyanov, S. M., Moldenhauer, G., Schuhmacher, J., Cochlovius, B., Von der Lieth, C.-W., Matys, E. R., & Little, M. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3156 · Cited by 202
Kettleborough, C. A., Saldanha, J., Heath, V. J., Morrison, C. J., & Bendig, M. M. (1991) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/4.7.773 · Cited by 197
Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting
Kortt, A. A., Dolezal, O., Power, B. E., & Hudson, P. J. (2001) · Biomolecular Engineering · doi:10.1016/s1389-0344(01)00090-9 · Cited by 173
Padlan, E. A. (1991) · Molecular Immunology · doi:10.1016/0161-5890(91)90163-e · Cited by 169
Bispecific human IgG by design
Carter, P. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00339-2 · Cited by 167
Epstein, A. L., Marder, R. J., Winter, J. N., et al. (1987) · PubMed · Cited by 147
Nagy, Z. A., Hubner, B., Löhning, C., Rauchenberger, R., Reiffert, S. U., Thomassen-Wolf, E., Zahn, S., Leyer, S., Schier, E. M., Zahradnik, A., et al. (2002) · Nature Medicine · doi:10.1038/nm736 · Cited by 141
Sáez‐Llorens, X., Castaño, E., Null, D. M., Steichen, J. J., Sánchez, P. J., Ramilo, O., Top, F. H., & Connor, E. M. (1998) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199809000-00007 · Cited by 136
Signaling antibodies in cancer therapy
Cragg, M. S., French, R. R., & Glennie, M. J. (1999) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)00010-2 · Cited by 119
Treatment of B cell malignancies with131I LYM-1 monoclonal antibodies
DeNardo, S. J., DeNardo, G. L., O'Grady, L. F., Hu, E. H.-L., Sytsma, V. M., Mills, S. L., Levy, N. B., Macey, D. J., Miller, C. H., & Epstein, A. L. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910410819 · Cited by 114
Nielsen, U. B., Adams, G. P., Weiner, L. M., et al. (2000) · PubMed · Cited by 110
Triabodies: Single chain Fv fragments without a linker form trivalent trimers
Iliades, P., Kortt, A. A., & Hudson, P. J. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00475-4 · Cited by 110
Irving, R. A., Coia, G., Roberts, A., Nuttall, S. D., & Hudson, P. J. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00341-0 · Cited by 96
Huls, G. A., Heijnen, I., Cuomo, M. E., Koningsberger, J. C., Wiegman, L., Boel, E. C. H., de Vries, A.-R. V. D. V., Loyson, S. A. J., Helfrich, W., Henegouwen, G. P. V. B., et al. (1999) · Nature Biotechnology · doi:10.1038/7023 · Cited by 95
Engineering Antibodies for Therapy
Presta, L. G. (2002) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201023378256 · Cited by 94
Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody
Holliger, P., Brissinck, J., Williams, R. L., Thielemans, K., & Winter, G. P. (1996) · Protein Engineering Design and Selection · doi:10.1093/protein/9.3.299 · Cited by 94
Kipriyanov, S. M., Cochlovius, B., Schäfer, H., Moldenhauer, G., Bähre, A., Gall, F. L., Knackmuss, S. H. J., & Little, M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.137 · Cited by 91
Preventing infectious disease with passive immunization
Zeitlin, L., Cone, R. A., Moench, T. R., & Whaley, K. J. (2000) · Microbes and Infection · doi:10.1016/s1286-4579(00)00355-5 · Cited by 91
Galun, E., Eren, R., Safadi, R., et al. (2002) · Hepatology · doi:10.1053/jhep.2002.31867 · Cited by 81
Treatment of Human B Cell Lymphoma Xenografts with a CD3 × CD19 Diabody and T Cells
Cochlovius, B., Kipriyanov, S. M., Stassar, M. J. J. G., Christ, O., Schuhmacher, J., Strauß, G., Moldenhauer, G., & Little, M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.2.888 · Cited by 80
IgA antibodies for cancer therapy
Dechant, M., & Valerius, T. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00105-6 · Cited by 79
Formatting antibody fragments to mediate specific therapeutic functions
Weir, A. N. C., Nesbitt, A. M., Chapman, A. P., Popplewell, A. G., & Lawson, A. D. G. (2002) · Biochemical Society Transactions · doi:10.1042/bst0300512 · Cited by 73
Treating human autoimmune disease by depleting B cells
Looney, R. J. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.10.863 · Cited by 71
A Review of Interleukin‐2 Receptor Antagonists in Solid Organ Transplantation
Berard, J. L., VELEZ, R., Freeman, R. B., & Tsunoda, S. M. (1999) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.19.15.1127.30582 · Cited by 66
Complement recruitment using bispecific diabodies
Kontermann, R. E., Wing, M. G., & Winter, G. P. (1997) · Nature Biotechnology · doi:10.1038/nbt0797-629 · Cited by 63
Production and Characterization of Protective Human Antibodies against Shiga Toxin 1
Mukherjee, J., Chios, K., Fishwild, D. M., et al. (2002) · Infection and Immunity · doi:10.1128/iai.70.10.5896-5899.2002 · Cited by 62
Groothuis, J. R., & Nishida, H. (2002) · Pediatrics International · doi:10.1046/j.1442-200x.2002.01558.x · Cited by 62
Physicochemical and biological properties of poly(ethylene glycol)-coupled immunoglobuling G
Suzuki, T., Kanbara, N., Tomono, T., Hayashi, N., & Shinohara, I. (1984) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/0167-4838(84)90268-1 · Cited by 60
Review article: the clinical role of anti‐TNFα antibody treatment in Crohn's disease
Bell, & Kamm, M. A. (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00777.x · Cited by 60
Bispecific antibodies targeting cancer cells
Peipp, M., & Valerius, T. (2002) · Biochemical Society Transactions · doi:10.1042/bst0300507 · Cited by 59
Cited by
The dawning era of polymer therapeutics
Duncan, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1088 · Cited by 3,269
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
Traggiai, E., Becker, S., Subbarao, K., Kolesnikova, L., Uematsu, Y., Gismondo, M. R., Murphy, B. R., Rappuoli, R., & Lanzavecchia, A. (2004) · Nature Medicine · doi:10.1038/nm1080 · Cited by 697
Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
Bannas, P., Hambach, J., & Koch-Nolte, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01603 · Cited by 572
“Nanomedicine (Lond) (2015) 10(1):161–74.”
BackgroundInfluentialAnimal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals
Butler, M. (2005) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-005-1980-8 · Cited by 469
Metadata
- Authors
- Brekke, O. H., & Sandlie, I.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2003-01-01
- Volume
- 2
- Issue
- 1
- Pages
- 52-62
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2058586537
- Cited by
- 550
- References
- 61
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.